Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society

[1] Goldhirsch A(2007)Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133-1144

[2] Wood WC(2003)Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study Clin Cancer Res 9 923-930

[3] Gelber RD(2008)Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J Clin Oncol 26 5697-5704

[4] Coates AS(2009)High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller J Clin Oncol 27 5700-5706

[5] Thürlimann B(2009)Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer J Clin Oncol 27 5693-5699

[6] Senn HJ(2014)HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort Cancer Med 3 134-142

[7] Joensuu H(2014)Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study J Clin Oncol 32 2142-2150

[8] Isola J(2014)Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system J Clin Oncol 32 2151-2158

[9] Lundin M(2014)Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer Clin Breast Cancer 14 309-314

[10] Salminen T(2012)Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer Cancer 118 3236-3243

[1] Goldhirsch A(2007)Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133-1144

[2] Wood WC(2003)Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study Clin Cancer Res 9 923-930

[3] Gelber RD(2008)Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J Clin Oncol 26 5697-5704

[4] Coates AS(2009)High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller J Clin Oncol 27 5700-5706

[5] Thürlimann B(2009)Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer J Clin Oncol 27 5693-5699

[6] Senn HJ(2014)HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort Cancer Med 3 134-142

[7] Joensuu H(2014)Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study J Clin Oncol 32 2142-2150

[8] Isola J(2014)Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system J Clin Oncol 32 2151-2158

[9] Lundin M(2014)Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer Clin Breast Cancer 14 309-314

[10] Salminen T(2012)Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer Cancer 118 3236-3243